The role of anaerobic microbiota in cystic fibrosis airway disease trajectory
厌氧微生物群在囊性纤维化气道疾病轨迹中的作用
基本信息
- 批准号:10985906
- 负责人:
- 金额:$ 49.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-14 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY / ABSTRACT
 Despite the recent surge in studies reporting on the prevalence and abundance of anaerobic
microbiota in the airways of individuals with cystic fibrosis (CF), their mechanistic contributions, if any, to
disease pathophysiology remain controversial and poorly understood. This knowledge gap is driven, in
part, by conflicting epidemiological and in vitro experimental data, a lack of suitable model systems to study
their interactions with the host, and the dearth of laboratory expertise in host-associated anaerobic
microbiology. Studies that generate greater insight into the role of anaerobes in CF lung infection,
particularly at early stages, are necessary to determine if, when, and how to target this group of organisms
therapeutically.
 Our team has shown that (i) anaerobes are early colonizers of the pediatric CF airways prior to the
acquisition of canonical pathogens, (ii) anaerobe bacterial communities elicit pro-inflammatory response
when co-cultured with bronchial epithelial cells, and (iii) anaerobe-mediated mucin degradation and cross-
feeding can shape the growth, virulence, and antibiotic susceptibility of canonical CF pathogens. Building
on these data, this project proposes to use a multi-disciplinary approach to investigate how individual
anaerobes interact with one another, the airway epithelium, and traditional pathogens (e.g., P. aeruginosa,
S. aureus) in the context of early CF airway disease. First, using an experimental microbiome model
system composed of 10 CF anaerobic species, we will determine how CF bacterial communities assemble
and how their assembly dynamics are shaped by host and microbial processes. Second, using an
innovative dual oxic-anoxic system that enables co-culture of anaerobic bacteria and airway epithelial cells,
we will use single-cell RNA sequencing to determine how anaerobes interact with the airway epithelium,
and how the host response varies by epithelial cell type. Finally, given that P. aeruginosa, S. aureus, and
other aerobic pathogens co-colonize with anaerobic microbiota and rapidly adapt to the airways as patients
age, we will use an in vitro experimental evolution approach to test whether early CF microbiota are
sufficient to drive the adaptation of canonical pathogens to the nutritional milieu of the CF airways.
 At the completion of these aims, we will have defined how individual anaerobes interact with one
another, the host, and traditional CF pathogens. In doing so, these studies will have a meaningful impact
on our mechanistic understanding of the role of airway microbiota in chronic airway disease and may
motivate future studies targeting specific anaerobic bacteria, or even promoting their growth, as a means
of improving clinical outcomes. Finally, we use CF as our model system, but this work is broadly applicable
to other acute and airway infections (e.g., COPD, sinusitis, ventilator associated pneumonias) in which
anaerobes have been implicated but their mechanistic contributions remain undefined.
项目摘要/摘要
尽管最近关于厌氧菌的流行率和丰度的研究激增
囊性纤维化(CF)患者呼吸道中的微生物群,如果有的话,它们对
疾病的病理生理学仍存在争议,且知之甚少。这种知识鸿沟是由
部分,由于流行病学和体外实验数据相互矛盾,缺乏合适的模型系统进行研究
它们与宿主的相互作用,以及缺乏与宿主相关的厌氧实验室专业知识
微生物学。更深入地了解厌氧菌在慢性支气管炎肺部感染中的作用,
特别是在早期阶段,对于确定是否、何时以及如何针对这组生物是必要的
从治疗上讲。
我们的团队已经证明:(I)厌氧菌是儿科CF呼吸道的早期定居者,在
获得典型病原体,(Ii)厌氧菌群落引发促炎反应
当与支气管上皮细胞共培养时,以及(Iii)厌氧菌介导的粘蛋白降解和交叉
喂食可以影响典型的CF病原体的生长、毒力和对抗生素的敏感性。建房
根据这些数据,该项目建议使用多学科方法来调查个人如何
厌氧菌与彼此、呼吸道上皮和传统病原体(例如,铜绿假单胞菌,
金黄色葡萄球菌)在早期慢性支气管炎呼吸道疾病的背景下。首先,使用一个实验性的微生物组模型
系统由10个碳纤维厌氧菌组成,我们将确定碳纤维细菌群落是如何组装的
以及它们的组装动态是如何由宿主和微生物过程塑造的。第二,使用
创新的双重缺氧系统,可实现厌氧细菌和呼吸道上皮细胞的共培养,
我们将使用单细胞RNA测序来确定厌氧菌如何与呼吸道上皮相互作用,
以及宿主反应如何随上皮细胞类型的不同而变化。最后,鉴于铜绿假单胞菌、金黄色葡萄球菌和
其他需氧病原菌与厌氧微生物群共同定植,并作为患者迅速适应呼吸道
年龄,我们将使用体外实验进化方法来测试早期CF微生物群是否
足以驱动典型病原体适应慢性阻塞性肺疾病呼吸道的营养环境。
在完成这些目标时,我们将定义单个厌氧菌如何与
另一种是寄主和传统病原菌。通过这样做,这些研究将产生有意义的影响
关于我们对呼吸道微生物区系在慢性呼吸道疾病中作用的机械理解,并可能
推动未来针对特定厌氧菌的研究,甚至促进它们的生长,作为一种手段
改善临床结果。最后,我们使用CF作为我们的模型系统,但这项工作具有广泛的适用性
其他急性和呼吸道感染(如慢性阻塞性肺病、鼻窦炎、呼吸机相关性肺炎)
厌氧菌已经被牵连,但它们的机制贡献仍然不确定。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
                item.title }}
{{ item.translation_title }}
- DOI:{{ item.doi }} 
- 发表时间:{{ item.publish_year }} 
- 期刊:
- 影响因子:{{ item.factor }}
- 作者:{{ item.authors }} 
- 通讯作者:{{ item.author }} 
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:{{ item.author }} 
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:{{ item.author }} 
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:{{ item.author }} 
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:{{ item.author }} 
数据更新时间:{{ patent.updateTime }}
Ryan Coulson Hunter其他文献
Ryan Coulson Hunter的其他文献
{{
              item.title }}
{{ item.translation_title }}
- DOI:{{ item.doi }} 
- 发表时间:{{ item.publish_year }} 
- 期刊:
- 影响因子:{{ item.factor }}
- 作者:{{ item.authors }} 
- 通讯作者:{{ item.author }} 
{{ truncateString('Ryan Coulson Hunter', 18)}}的其他基金
The role of anaerobic microbiota in cystic fibrosis airway disease trajectory
厌氧微生物群在囊性纤维化气道疾病轨迹中的作用
- 批准号:10716654 
- 财政年份:2023
- 资助金额:$ 49.39万 
- 项目类别:
Bacterial mucin degradation in cystic fibrosis airway disease.
囊性纤维化气道疾病中的细菌粘蛋白降解。
- 批准号:9398656 
- 财政年份:2017
- 资助金额:$ 49.39万 
- 项目类别:
Bacterial mucin degradation in cystic fibrosis airway disease.
囊性纤维化气道疾病中的细菌粘蛋白降解。
- 批准号:10163251 
- 财政年份:2017
- 资助金额:$ 49.39万 
- 项目类别:
Spatial characterization of microbial communities in the cystic fibrosis lung
囊性纤维化肺微生物群落的空间特征
- 批准号:8722016 
- 财政年份:2013
- 资助金额:$ 49.39万 
- 项目类别:
Spatial characterization of microbial communities in the cystic fibrosis lung
囊性纤维化肺微生物群落的空间特征
- 批准号:8699293 
- 财政年份:2013
- 资助金额:$ 49.39万 
- 项目类别:
Spatial characterization of microbial communities in the cystic fibrosis lung
囊性纤维化肺微生物群落的空间特征
- 批准号:8879195 
- 财政年份:2013
- 资助金额:$ 49.39万 
- 项目类别:
Spatial characterization of microbial communities in the cystic fibrosis lung
囊性纤维化肺微生物群落的空间特征
- 批准号:8353669 
- 财政年份:2012
- 资助金额:$ 49.39万 
- 项目类别:
相似海外基金
Fecal Microbiota Transfer Attenuates Aged Gut Dysbiosis and Functional Deficits after Traumatic Brain Injury
粪便微生物群转移可减轻老年肠道菌群失调和脑外伤后的功能缺陷
- 批准号:10818835 
- 财政年份:2023
- 资助金额:$ 49.39万 
- 项目类别:
Fecal Microbiota Transfer Attenuates Aged Gut Dysbiosis and Functional Deficits after Traumatic Brain Injury
粪便微生物群转移可减轻老年肠道菌群失调和脑外伤后的功能缺陷
- 批准号:10573109 
- 财政年份:2023
- 资助金额:$ 49.39万 
- 项目类别:
Microbiome targeted nutrition to improve immune function during critical illness
微生物组靶向营养可改善危重疾病期间的免疫功能
- 批准号:10751673 
- 财政年份:2023
- 资助金额:$ 49.39万 
- 项目类别:
A Novel Small Molecule Therapeutic for Acute Graft Versus Host Disease
一种治疗急性移植物抗宿主病的新型小分子疗法
- 批准号:10759657 
- 财政年份:2023
- 资助金额:$ 49.39万 
- 项目类别:
The role of anaerobic microbiota in cystic fibrosis airway disease trajectory
厌氧微生物群在囊性纤维化气道疾病轨迹中的作用
- 批准号:10716654 
- 财政年份:2023
- 资助金额:$ 49.39万 
- 项目类别:
Role of sulfide in oral microbiota-host interactions that promote periodontitis
硫化物在促进牙周炎的口腔微生物群与宿主相互作用中的作用
- 批准号:10828614 
- 财政年份:2023
- 资助金额:$ 49.39万 
- 项目类别:
Type 2 diabetes, sodium glucose, cotransporter-2 (SGLT2) inhibitors and the vaginal microbiota
2 型糖尿病、葡萄糖钠、协同转运蛋白 2 (SGLT2) 抑制剂和阴道微生物群
- 批准号:10462949 
- 财政年份:2022
- 资助金额:$ 49.39万 
- 项目类别:
Mechanisms of microbiome-driven cardiac allograft outcomes
微生物组驱动的同种异体心脏移植结果的机制
- 批准号:10477625 
- 财政年份:2022
- 资助金额:$ 49.39万 
- 项目类别:
Microbiota-based probiotics to treat inborn errors in metabolism
基于微生物群的益生菌可治疗先天性代谢缺陷
- 批准号:10365689 
- 财政年份:2022
- 资助金额:$ 49.39万 
- 项目类别:
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM:  PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERSTASK ORDER TITLE: VACCINES AGAINS
基本标题:预防临床前药物开发计划:临床前疗效和中间终点 BIOMAKERSTASK 订单标题:再次疫苗
- 批准号:10651935 
- 财政年份:2022
- 资助金额:$ 49.39万 
- 项目类别:

 刷新
              刷新
            
















 {{item.name}}会员
              {{item.name}}会员
            



